Search results for "Highlights"


 
Results 61 - 70 of about 418 for "Highlights".
Sort by: Relevance | Newest | Oldest

Severe insulin-resistant diabetes associated with better metabolic surgery outcomes

Patients with severe insulin-resistant diabetes had better outcomes after metabolic surgery than those with mild obesity-related diabetes or severe insulin-deficient diabetes, both in terms of type 2 diabetes remission and renal function, with no additional surgical risk.
https://diabetes.acponline.org/archives/2022/03/11/3.htm
11 Mar 2022

Interventions uncommon for prediabetes in primary care

A U.S. retrospective study found that while 63.4% of prediabetes patients had repeated glycemic testing over one year of follow-up, 10.4% had a primary care visit with a coded diagnosis of prediabetes, 1.0% were referred for nutrition services, and 5.4% were prescribed metformin.
https://diabetes.acponline.org/archives/2022/03/11/2.htm
11 Mar 2022

Association of inflammation with mortality in COVID-19 didn't differ by diabetes status

A single-center, case-control study of patients who were hospitalized with COVID-19 found a link between elevated levels of IL-6, IL-8, and interferon-γ-induced protein 10 and mortality risk, regardless of whether patients had type 2 diabetes.
https://diabetes.acponline.org/archives/2022/01/14/2.htm
14 Jan 2022

Nearly one-third of patients were nonadherent to newly prescribed SGLT-2 inhibitors, GLP-1 receptor agonists

Factors associated with not filling a new prescription for a sodium-glucose cotransporter-2 (SGLT-2) inhibitor or a glucagon-like peptide-1 (GLP-1) receptor agonist included older age, Black race, male sex, certain comorbid conditions, and having a primary care clinician prescribe the drug, a study found.
https://diabetes.acponline.org/archives/2022/02/11/2.htm
11 Feb 2022

Obesity increasing in type 1 diabetes, associated with higher risk for chronic kidney disease

Obesity in type 1 diabetes rose from 2004 to 2018, and patients with type 1 had a higher adjusted prevalence of low estimated glomerular filtration rate and albuminuria than those with type 2, an analysis of one health system found.
https://diabetes.acponline.org/archives/2022/02/11/3.htm
11 Feb 2022

Metformin use during pregnancy not associated with adverse outcomes in children

A industry-conducted cohort study in Finland found that childhood obesity, hypoglycemia, hyperglycemia, diabetes, and challenges in motor-social development did not appear to be associated with in utero exposure to metformin or metformin and insulin versus insulin alone.
https://diabetes.acponline.org/archives/2022/01/14/3.htm
14 Jan 2022

Study finds long-term reductions in cardiovascular risk factors with SGLT-2 inhibitors

While the meta-analysis also found durable reductions in macrovascular complications and mortality with sodium-glucose cotransporter-2 (SGLT-2) inhibitors versus placebo, there were insufficient data comparing the drug class to other antihyperglycemic medications.
https://diabetes.acponline.org/archives/2021/12/10/2.htm
10 Dec 2021

Adults with diabetes more likely to report mental stress during the COVID-19 pandemic

An online survey of U.S. adults in mid-2020, most of whom were White women, found that those with diabetes were less likely to report resilience and more likely to experience depression than adults without diabetes.
https://diabetes.acponline.org/archives/2021/12/10/3.htm
10 Dec 2021

No differences seen in outcomes with one-step vs. two-step gestational diabetes screening

The one-step screening process, which used a two-hour fasting glucose tolerance test, found more cases of gestational diabetes in a randomized trial, but perinatal and maternal complications did not differ.
https://diabetes.acponline.org/archives/2021/03/12/2.htm
12 Mar 2021

Choice of SGLT-2 inhibitors, GLP-1 receptor agonists should be based on individual risk

A meta-analysis comparing sodium-glucose cotransporter-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists found differing effects, including that the SGLT-2 inhibitors affected heart failure outcomes while GLP-1 receptor agonists reduced stroke risk.
https://diabetes.acponline.org/archives/2021/02/12/3.htm
12 Feb 2021

Result Page: Prev   2   3   4   5   6   7   8   9   10   11   Next